What is the price-to-earnings ratio of Immunitybio?
The price-earnings ratio of Immunitybio is currently 43.21.
Immunitybio P/S 2024
Immunitybio P/S
43.21
Ticker
IBRX
ISIN
US45256X1037
WKN
A2QQ2E
As of Jun 16, 2024, Immunitybio's P/S ratio stood at 43.21, a 1,700.42% change from the 2.4 P/S ratio recorded in the previous year.
The Immunitybio P/S history
Immunitybio Aktienanalyse
What does Immunitybio do?
Translate this as near as possible to English. ImmunityBio Inc is a biotechnology company specializing in innovative methods to combat cancer and other serious diseases. The company was founded in 2015 by esteemed biotech entrepreneur and scientist, Dr. Patrick Soon-Shiong. The idea behind ImmunityBio was to create a company focused on developing advanced immunotherapies that involve the human immune system in the fight against cancer. The business model is based on several business units, including research and development, diagnostics, and therapeutics. In recent years, the company has expanded through a series of significant acquisitions and mergers, including CytRx Corporation, NantWorks LLC, and NantKwest Inc. Together, these mergers have expanded and united the resources and expertise of ImmunityBio to achieve new advancements in oncology. ImmunityBio has also developed a variety of products focused on strengthening the immune system, including its leading drug, INT-001, intended for the treatment of lung, pancreatic, breast, stomach, and colorectal cancer. The company has also developed diagnostic products, such as the ImmuneMap™ test, which analyzes the patient's immune profile and can contribute to better combinations of existing immunotherapies. Another business unit is the service department, which focuses on providing services related to precision medicine. ImmunityBio offers a wide range of personalized drugs and services to help provide patients with better and more effective treatment. The company also has an extensive pipeline of immunotherapies for various indications, including several clinical trials for the treatment of lung cancer, pancreatic cancer, and breast cancer. The portfolio includes both single agents and combination therapies, which the company will introduce after a rigorous phase 1 study. Overall, ImmunityBio has an ambitious goal of being a leading player in the innovation of immunotherapies. Through a multidisciplinary approach to the discovery and development of new treatments, ImmunityBio is working to defeat cancer by strengthening the immune system and improving the quality of life for patients worldwide. Immunitybio ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Immunitybio's P/S Ratio
Immunitybio's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Immunitybio's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Immunitybio's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Immunitybio’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Immunitybio Stock
How has the price-earnings ratio of Immunitybio changed compared to last year?
The price-to-earnings ratio of Immunitybio has increased by 1,700.42% increased compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Immunitybio high compared to other companies?
Yes, the price-to-earnings ratio of Immunitybio is high compared to other companies.
How does an increase in the price-earnings ratio of Immunitybio affect the company?
An increase in the price-earnings ratio of Immunitybio would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Immunitybio affect the company?
A decrease in the price-earnings ratio of Immunitybio would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Immunitybio?
Some factors that influence the price-earnings ratio of Immunitybio are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Immunitybio pay?
Over the past 12 months, Immunitybio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunitybio is expected to pay a dividend of 0 USD.
What is the dividend yield of Immunitybio?
The current dividend yield of Immunitybio is .
When does Immunitybio pay dividends?
Immunitybio pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Immunitybio?
Immunitybio paid dividends every year for the past 0 years.
What is the dividend of Immunitybio?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Immunitybio located?
Immunitybio is assigned to the 'Health' sector.
Wann musste ich die Aktien von Immunitybio kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Immunitybio from 6/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/16/2024.
When did Immunitybio pay the last dividend?
The last dividend was paid out on 6/16/2024.
What was the dividend of Immunitybio in the year 2023?
In the year 2023, Immunitybio distributed 0 USD as dividends.
In which currency does Immunitybio pay out the dividend?
The dividends of Immunitybio are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Immunitybio
Our stock analysis for Immunitybio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunitybio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
